Type: Drug-device combination product candidate combining Optinose’s nasal Exhalation Delivery System (EDS) technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19.
Status: Optinose said June 30 it will begin to develop OPN-19 by supporting initial development stages from operating expanses, and by seeking grants, partnerships, and/or other sources of capital to fund future development.
Optinose said it expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials, since components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: